1상모집 중
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of the GSK 4-component Strep A Vaccine With Aluminum Hydroxide (Alum) or AS37 in Healthy Young Adults
연구 개요
The purpose of this study is to assess the safety of 3 doses of 2 new Strep A vaccine formulations, one with an Alum adjuvant, and the other with AS37 adjuvant. The Strep A vaccine will be tested for the first time in humans, in healthy young adults 18 to 25 years of age. The study will also assess if the vaccines have any immediate reactions and if they induce an immune response. A low, medium, and high dose of each formulation of the vaccine will be assessed in sequence.
- 스폰서
- 리드: GSK
- 적응증
- Streptococcal Infections
- 중재
- Low dose Strep A Alum, Medium dose Strep A Alum, High dose Strep A Alum, Low dose Strep A AS37, Medium dose Strep A AS37, High dose Strep A AS37, Strep A Alum Placebo
- 목표 등록
- 108명
- 시작일
- 2025-07-31
- 완료(예정)
- 2026-11-30
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.